Adial Pharmaceuticals Inc (ADIL)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Cary J. Claiborne
Employees:
20
1180 SEMINOLE TRAIL, SUITE 495, CHARLOTTESVILLE, VA 22902
434-422-9800

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction.

Data derived from most recent annual or quarterly report
Market Cap 9.049 Million Shares Outstanding25.854 Million Avg 30-day Volume 1.45 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.12
Price to Revenue0.0 Debt to Equity0.151 EBITDA-15.741 Million
Price to Book Value1.7376 Operating Margin0.0 Enterprise Value4.463 Million
Current Ratio5.104 EPS Growth0 Quick Ratio4.335
1 Yr BETA 0.5439 52-week High/Low 2.27 / 0.2 Profit Margin0.0
Operating Cash Flow Growth3.136 Altman Z-Score-14.4707 Free Cash Flow to Firm -10.626 Million
View SEC Filings from ADIL instead.

View recent insider trading info

Adial Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding ADIL (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADIL

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-01-03 by STILLEY WILLIAM B. III
  • 4: filed on 2022-09-20 by CLAIBORNE CARY J
  • 4: filed on 2022-08-23 by STILLEY WILLIAM B. III
  • 4: filed on 2022-08-22 by CLAIBORNE CARY J
  • 4: filed on 2022-06-28 by GOODMAN TONY
  • 4: filed on 2022-02-25 by JOHNSON BANKOLE A.
  • 4: filed on 2022-02-25 by GOODMAN TONY
  • 4: filed on 2022-02-25 by TRULUCK JOSEPH
  • 4: filed on 2022-02-25 by STILLEY WILLIAM B. III
  • 4: filed on 2022-02-25 by SCHUYLER KEVIN

    • Events (8k)

  • 8-K: filed on 2023-03-31:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-02:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-21:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-01:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 1.01: Entry into a Material Definitive Agreement
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-26:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    STILLEY WILLIAM B. III

    • Director
    		 1,020,979 2022-12-30 2

    CLAIBORNE CARY J CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,100,000 2022-09-19 2

    GOODMAN TONY

    • Director
    		 25,000 2022-06-27 1

    ANDERSON J. KERMIT

    • Director
    		 40,000 2022-02-23 0

    TRULUCK JOSEPH CHIEF FINANCIAL OFFICER

    • Officer
    		 100,000 2022-02-23 0

    SCHUYLER KEVIN

    • Director
    		 40,000 2022-02-23 0

    JOHNSON BANKOLE A. CHIEF MEDICAL OFFICER

    • Officer
    		 35,000 2022-02-23 0

    GILLILAND ROBERTSON H.

    • Director
    		 40,000 2022-02-23 0

    NEWMAN JAMES W. JR.

    • Director
    		 40,000 2022-02-23 0

    REICH JACK W

    • Director
    		 0 2020-05-19 0

    JOHNSON BANKOLE A.

    EN FIDECOMISO DE MI VIDA 11/23/2010 TRUST

    • Director
    • 10% Owner
    		 1,467,420 2018-07-31 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 22:15:04 UTC -0.122 4.942 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 21:45:05 UTC -0.122 4.942 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 21:15:03 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 20:45:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 20:15:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 19:45:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 19:15:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 18:45:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 18:15:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 17:45:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 17:15:03 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 16:45:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 16:15:04 UTC -0.3204 5.1404 150000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 15:45:04 UTC -0.8135 5.6335 250000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 15:15:03 UTC -0.8135 5.6335 250000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 14:45:04 UTC -0.8135 5.6335 250000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 14:15:04 UTC -0.8135 5.6335 250000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 13:45:03 UTC -1.5298 6.3498 250000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 13:15:03 UTC -1.5298 6.3498 250000
    ADIAL PHARMACEUTICALS INC ADIL 2023-03-31 12:45:03 UTC -1.5298 6.3498 250000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADIL -1700.0 shares, $-362.1 2022-12-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments